Aqualung Therapeutics, an early-stage immunotherapeutics company with an anti-inflammatory therapeutic platform for life-threatening unchecked inflammation, has closed a $2.5M convertible note fundraise led by a $1.5M investment from JSR Life Sciences, LLC.
Related